DOI QR코드

DOI QR Code

Plasma Nuclear Factor Kappa B and Serum Peroxiredoxin 3 in Early Diagnosis of Hepatocellular Carcinoma

  • Ismail, Saber (Department of Tropical Medicine & Infectious Diseases, Faculty of Medicine, Tanta University) ;
  • Mayah, Wael (Department of Tropical Medicine & Infectious Diseases, Faculty of Medicine, Tanta University) ;
  • Battia, Hassan El (Department of Tropical Medicine & infectious Diseases, Faculty of Medicine, Kafrelsheikh University) ;
  • Gaballah, Hanaa (Department of Medical Biochemistry, Faculty of Medicine, Tanta University) ;
  • Jiman-Fatani, Asif (Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University) ;
  • Hamouda, Hala (Department of Medical Biochemistry, Faculty of Medicine, Tanta University) ;
  • Afifi, Mohamed A. (Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University) ;
  • Elmashad, Nehal (Department of Clinical Oncology, Faculty of Medicine, Tanta University) ;
  • Saadany, Sherif El (Department of Tropical Medicine & Infectious Diseases, Faculty of Medicine, Tanta University)
  • Published : 2015.03.09

Abstract

Background: Early diagnosis of hepatocellular carcinoma (HCC) is the most important step in successful treatment. However, it is usually rare due to the lack of a highly sensitive specific biomarker so that the HCC is usually fatal within few months after diagnosis. The aim of this work was to study the role of plasma nuclear factor kappa B (NF-${\kappa}B$) and serum peroxiredoxin 3 (PRDX3) as diagnostic biomarkers for early detection of HCC in a high-risk population. Materials and Methods: Plasma nuclear factor kappa B level (NF-${\kappa}B$) and serum peroxiredoxin 3 (PRDX3) levels were measured using enzyme linked immunosorbent assay (ELISA), in addition to alpha-fetoprotein (AFP) in 72 cirrhotic patients, 64 patients with HCC and 29 healthy controls. Results: NF-${\kappa}B$ and PRDX3 were significantly elevated in the HCC group in relation to the others. Higher area under curve (AUC) of 0.854 (for PRDX3) and 0.825 (for NF-${\kappa}B$) with sensitivity of 86.3% and 84.4% and specificity of 75.8% and 75.4% respectively, were found compared to AUC of alpha-fetoprotein (AFP) (0.65) with sensitivity of 72.4% and specificity of 64.3%. Conclusions: NF-${\kappa}B$ and PRDX3 may serve as early and sensitive biomarkers for early detection of HCC facilitating improved management. The role of nuclear factor kappa B (NF-${\kappa}B$) as a target for treatment of liver fibrosis and HCC must be widely evaluated.

Keywords

Nuclear factor kappa B;peroxiredoxin 3;hepatocellular carcinoma;early diagnosis

References

  1. Altekruse SF, McGlynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27, 1485-91. https://doi.org/10.1200/JCO.2008.20.7753
  2. Arsura M, Cavin LG (2005). Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett, 229, 157-69. https://doi.org/10.1016/j.canlet.2005.07.008
  3. Basu A, Banerjee H, Rojas H, et al (2011). Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate, 71, 755-65. https://doi.org/10.1002/pros.21292
  4. Beale G, Chattopadhyay D, Gray J, et al (2008). AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer, 8, 200-8. https://doi.org/10.1186/1471-2407-8-200
  5. Bonacchi A, Petrai I, Defranco RM, et al (2003). The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology, 125, 1060-76. https://doi.org/10.1016/S0016-5085(03)01194-6
  6. Bosch FX, Ribes J, Diaz M, Cleries R (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, 5-16. https://doi.org/10.1016/S0016-5085(04)01170-9
  7. Bouchard MJ, Navas-Martin S (2011). Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett, 305, 123-43. https://doi.org/10.1016/j.canlet.2010.11.014
  8. Bruix J, Sherman M (2005). Practice guidelines committee, American association for the study of liver diseases. management of hepatocellular carcinoma. Hepatology, 42, 1208-36. https://doi.org/10.1002/hep.20933
  9. Cabibbo G, Craxi A (2101). Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 14, 352-5.
  10. Chan HL, Tsang SW, Leung NW, et al (2002). Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol, 97, 1211-5. https://doi.org/10.1111/j.1572-0241.2002.05706.x
  11. Dietz KJ, Horling F, Konig J, Baier M (2002). The function of oroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulation. J Exp Bot, 53, 1321-9. https://doi.org/10.1093/jexbot/53.372.1321
  12. Dominguez I, Sonenshein GE, Seldin DC (2009). Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NFkappaB signaling: linking development and cancer. Cell Mol Life Sci, 66, 1850-7. https://doi.org/10.1007/s00018-009-9153-z
  13. Gaballah HH, Zakaria SS, Ismail SA (2014). Activity and expression pattern of NF-${\kappa}B$ /P65 in peripheral blood from hepatocellular carcinoma patients - link to hypoxia inducible factor-$1{\alpha}$. Asian Pac J Cancer Prev, 15, 6911-7. https://doi.org/10.7314/APJCP.2014.15.16.6911
  14. Gomaa AJ, Khan SA, Leen EL, Waked I, Taylor-Robinson SD (2009). Diagnosis of hepatocellular carcinoma. World J Gastroenterol, 15, 1301-14. https://doi.org/10.3748/wjg.15.1301
  15. Guo J, Loke J, Zheng F, et al (2009). Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology, 49, 960-8. https://doi.org/10.1002/hep.22697
  16. Haruki K, Shiba H, Fujiwara Y, et al (2013). Inhibition of nuclear factor-${\kappa}B$ enhances the antitumor effect of tumor necrosis factor-${\alpha}$ gene therapy for hepatocellular carcinoma in mice. Surgery, 154, 468-78. https://doi.org/10.1016/j.surg.2013.05.037
  17. Huang HC, Zheng S, VanBuren V, Zhao Z (2010). Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat, 9, 219-30. https://doi.org/10.1177/153303461000900301
  18. Huh JY, Kim Y, Jeong J, et al (2012). Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal, 16, 229-43. https://doi.org/10.1089/ars.2010.3766
  19. Hung CH, Lee CM, Kuo FY, et al (2008). Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C. Liver Int, 28, 339-46. https://doi.org/10.1111/j.1478-3231.2008.01676.x
  20. Iakova P, Timchenko L, Timchenko NA (2011). Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol, 21, 28-34.
  21. Jo M, Nishikawa T, Nakajima T, et al (2011). Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroenterol, 46, 809-21. https://doi.org/10.1007/s00535-011-0392-z
  22. Kim K, Yu M, Han S et al (2009). Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep, 21, 1391-6.
  23. Li XQ, Zhang SL, Cai Z, et al (2009). Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett, 275, 109-16. https://doi.org/10.1016/j.canlet.2008.10.019
  24. Liu X, Feng R, Du L (2010). The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett, 584, 3185-92. https://doi.org/10.1016/j.febslet.2010.06.002
  25. Luedde T, Schwabe RF (2011). NF-${\kappa}B$ in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 8, 108-18. https://doi.org/10.1038/nrgastro.2010.213
  26. Macias Rodriguez MA, Rendon Unceta P, Tejada Cabrera M, et al (2000). Risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Rev Esp Enferm Dig, 92, 458-69.
  27. Makuuchi M, Kokudo N, Arii S, et al (2008). Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res, 38, 37-51. https://doi.org/10.1111/j.1872-034X.2007.00216.x
  28. Marra M, Sordelli IM, Lombardi A, et al (2011). Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med, 10, 9:171.
  29. Mendy M, Walton R (2009). Molecular pathogenesis and early detection of hepatocellular carcinoma-perspectives from West Africa. Cancer Lett, 286, 44-51. https://doi.org/10.1016/j.canlet.2009.04.039
  30. Miura K, Kodama Y, Inokuchi S, et al (2010). Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology, 139, 323-34. https://doi.org/10.1053/j.gastro.2010.03.052
  31. Nagaoka S, Yatsuhashi H, Hamada H, et al (2003). The desgamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer, 98, 2671-7. https://doi.org/10.1002/cncr.11839
  32. Naugler WE, Karin M (2008). NF-kappa B and canceridentifying targets and mechanisms. Curr Opin Genet Dev, 18, 19-26. https://doi.org/10.1016/j.gde.2008.01.020
  33. Nonn L, Berggren M, Powis G (2003). Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res, 1, 682-9.
  34. Poon D, Anderson BO, Chen LT, et al (2009). Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit. Lancet Oncol, 10, 1111-8. https://doi.org/10.1016/S1470-2045(09)70241-4
  35. Punsawad C, Krudsood S, Maneerat Y, et al (2012). Activation of nuclear factor kappa B in peripheral blood mononuclear cells from malaria patients. Malar J, 11, 191. https://doi.org/10.1186/1475-2875-11-191
  36. Qiao B, Wang J, Xie J, et al (2012). Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med, 29, 832-40.
  37. Rabilloud T, Heller M, Gasnier F, et al (2002). Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem, 277, 19396-401. https://doi.org/10.1074/jbc.M106585200
  38. Schwabe RF, Seki E, Brenner DA (2006). Toll-like receptor signaling in the liver. Gastroenterology, 130, 1886-900. https://doi.org/10.1053/j.gastro.2006.01.038
  39. Seki E, De Minicis S, Osterreicher CH, et al (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med, 13, 1324-32. https://doi.org/10.1038/nm1663
  40. Shi L, Wu LL, Yang JR, et al (2014). Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessment of prognosis of hepatocellular carcinoma in Chinese patients. Asian Pac J Cancer Prev, 15, 2979-86 https://doi.org/10.7314/APJCP.2014.15.7.2979
  41. Sunami Y, Leithauser F, Gul S, et al (2012). Hepatic activation of IKK/NF${\kappa}B$ signaling induces liver fibrosis via macrophagemediated chronic inflammation. Hepatology, 56, 1117-28. https://doi.org/10.1002/hep.25711
  42. Tai DI, Tsai SL, Chen YM, et al (2000). Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology, 31, 656-64. https://doi.org/10.1002/hep.510310316
  43. Teofanescu I, Gologan E, Stefanescu E, Balan G (2010). Surveillance of cirrhosis for hepatocellular carcinoma--clinical validation of new serological biomarkers for improved diagnosis. Rev Med Chir Soc Med Nat Iasi, 114, 39-46.
  44. Thomas M, Zhu A (2005). Hepatocellular carcinoma: the need for progress. J Clin Oncol, 23, 2892-9. https://doi.org/10.1200/JCO.2005.03.196
  45. Trachootham D, Alexandre J, Huang P (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 8, 579-91. https://doi.org/10.1038/nrd2803
  46. Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA (2011). Level of ${\alpha}$-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol, 9, 989-94. https://doi.org/10.1016/j.cgh.2011.07.026
  47. Wilkins T, Malcolm JK, Raina D, Schade RR (2010). Hepatitis C: diagnosis and treatment. Am Fam Physician, 81, 1351-7.
  48. Wonsey DR, Zeller KI, Dang CV (2002). The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci U S A, 99, 6649-54. https://doi.org/10.1073/pnas.102523299
  49. Wu W, Yao DF, Qiu LW, et al (2009). Characteristics of hepatic nuclear-transcription factor-kappa B expression and quantitative analysis in rat hepatocarcinogenesis. Hepatobiliary Pancreat Dis Int, 8, 504-9.
  50. Wu XY, Fu ZX, Wang XH (2010). Peroxiredoxins in colorectal neoplasms. Histol Histopathol, 25, 1297-303.
  51. Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82. https://doi.org/10.1007/s00535-010-0278-5
  52. Yokoo H, Yasuda J, Nakanishi K, et al (2011). Clinicopathological significance of nuclear factor-${\kappa}B$ activation in hepatocellular carcinoma. Hepatol Res, 41, 240-9. https://doi.org/10.1111/j.1872-034X.2010.00758.x
  53. Youns MM, Abdel Wahab AH, Hassan ZA, Attia MS (2013). Serum talin-1 is a potential novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Asian Pac J Cancer Prev, 14, 3819-23. https://doi.org/10.7314/APJCP.2013.14.6.3819
  54. Yu SC, Yeung DT, So NM (2004). Imaging features of hepatocellular carcinoma. Clin Radiol, 59, 145-56. https://doi.org/10.1016/S0009-9260(03)00316-7
  55. Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev, 14, 6721-6. https://doi.org/10.7314/APJCP.2013.14.11.6721
  56. Zhang F, Wang Q, Ye L, Feng Y, Zhang X (2010). Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-kappaB/p65 in hepatoma cells. J Med Virol, 82, 920-8. https://doi.org/10.1002/jmv.21753
  57. Zhang ZM, Zhang YM, Gao S, et al (2014). Treatment efficacy and prognostic factors for huge HCC based on Barcelona clinic liver cancer staging. Asian Pac J Cancer Prev, 15, 8823-8. https://doi.org/10.7314/APJCP.2014.15.20.8823

Cited by

  1. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4769
  2. Inhibits Growth and Promotes Invasion and Extracellular Matrix Degradation in Hepatocellular Carcinoma Cells vol.15, pp.5, 2016, https://doi.org/10.1021/acs.jproteome.5b01125
  3. Effects of Epothilone A in Combination with the Antidiabetic Drugs Metformin and Sitagliptin in HepG2 Human Hepatocellular Cancer Cells: Role of Transcriptional Factors NF-κB and p53 vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.993